Molecure Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
71
- Stock Symbol
-
MOC
- Share Price
-
$1.36
- (As of Thursday Closing)
Molecure General Information
Description
Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs.
Contact Information
Website
www.molecure.comCorporate Office
- Żwirki i Wigury 101
- Warsaw, 02-089
- Poland
Corporate Office
- Żwirki i Wigury 101
- Warsaw, 02-089
- Poland
Molecure Stock Performance
As of 12-Nov-2026, Molecure’s stock price is $1.36. Its current market cap is $33.6M with 24.7M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.36 | $1.40 | $1.31 - $2.59 | $33.6M | 24.7M | 51.8K | -$0.26 |
Molecure Financials Summary
As of 30-Sep-2025, Molecure has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 34,442 | 35,873 | 63,263 | 28,353 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (5,770) | (7,178) | (7,122) | (3,555) |
| Net Income | (6,321) | (7,854) | (6,750) | (3,421) |
| Total Assets | 26,662 | 27,650 | 28,134 | 31,477 |
| Total Debt | 1,533 | 1,759 | 1,789 | 1,461 |
Molecure Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Molecure Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Molecure Patents
Molecure Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| ES-3056105-T3 | Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine | Active | 25-Sep-2019 | ||
| US-10329310-B2 | Arginase inhibitors and their therapeutic applications | Active | 29-Dec-2014 | ||
| US-20180009830-A1 | Arginase inhibitors and their therapeutic applications | Active | 29-Dec-2014 | C07F5/025 |
Molecure Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Molecure ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Molecure FAQs
-
When was Molecure founded?
Molecure was founded in 2012.
-
Where is Molecure headquartered?
Molecure is headquartered in Warsaw, Poland.
-
What is the size of Molecure?
Molecure has 71 total employees.
-
What industry is Molecure in?
Molecure’s primary industry is Drug Discovery.
-
Is Molecure a private or public company?
Molecure is a Public company.
-
What is Molecure’s stock symbol?
The ticker symbol for Molecure is MOC.
-
What is the current stock price of Molecure?
As of 12-Nov-2026 the stock price of Molecure is $1.36.
-
What is the current market cap of Molecure?
The current market capitalization of Molecure is $33.6M.
-
What is Molecure’s annual earnings per share (EPS)?
Molecure’s EPS for 12 months was -$0.26.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
